The North East region has a particularly strong health and life science sector and supports a large number of intermediaries, many with strong industrial capabilities.
We’re able to make, develop and trial our products all within one small area which makes the North East a very economical place to do business.
There is a huge amount of expertise and knowledge in the region as well as a talented pool of graduates and PhD students from the local universities.
There’s also a fantastic quality of life on offer, which makes the North East a great place to live as well as work.
Iksuda Therapeutics (formerly Glythera) is a drug development company specialising in the development of stable, safer and superior Antibody Drug Conjugates (ADCs) for the treatment of difficult to treat solid tumours.
From its bases in Newcastle upon Tyne and Boston, MA, it has four ADCs in pre-clinical development and anticipates entering the clinic by 2021. Iksuda is focused on improving the lives of patients living with cancer.
Iksuda’s new state-of-the-art facility will be at the Newcastle Helix development. It will be home to PhD-trained scientists including chemists and biologists working across candidate discovery, development and the pre-clinical assessment of its lead ADC candidates. Iksuda works closely from its Newcastle Headquarters with its national and international partners within the life science sector.